

해외 바이오의약품 임상 현황 ('24년 3월 3주)

한국바이오의약품협회, 2024.03.26.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2024.03.18.~2024.03.24.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06259552	A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors	Biological: SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody	SparX Biotech(Jiangsu) Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06259552
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Biological: Autologous BAFFR-targeting CAR T Cells Drug: Bendamustine Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration and Biopsy Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Procedure: Leukapheresis Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography	Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06191887
NCT06150664	A Phase 1 of CTX-8371 in Patients With Advanced Malignancies	Drug: CTX-8371	Compass Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06150664
NCT06125197	Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer	Biological: TILT-123 Biological: Pembrolizumab	TILT Biotherapeutics Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06125197
NCT06112847	Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma	Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Other: Electronic Health Record Review Biological: Epcoritamab Drug: Lenalidomide Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06112847
NCT06326060	A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight	Drug: NNC0519-0130 Drug: Placebo Drug: Tirzepatide	Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06326060
NCT06326047	A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes	Drug: NNC0519-0130 Drug: Placebo Drug: Tirzepatide	Novo Nordisk A/S	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06326047
NCT06323174	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06323174
NCT05948566	Strategy for Improving Stroke Treatment Response	Biological: TS23	Translational Sciences, Inc. University of Cincinnati National Institute of Neurological Disorders and Stroke (NINDS) Medical University of South Carolina University of Arizona	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05948566

해외 바이오의약품 임상 현황 ('24년 3월 3주)

한국바이오의약품협회, 2024.03.26.

○ 중국 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06316427	Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma	Drug: Autologous CD7 CAR T-cell Drug: Prior-HSCT donor-derived CD7 CAR T-cell Drug: New donor-derived CD7 CAR T-cell	Beijing GoBroad Hospital	Phase 1 Phase 2	
NCT06313697	A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult	Biological: GR2102 injection Biological: placebo	Genrix (Shanghai) Biopharmaceutical Co., Ltd.	Phase 1	
NCT06301399	Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study	Drug: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy	Tianjin Medical University Cancer Institute and Hospital	Phase 2	
NCT06292689	A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer	Drug: Cardunolizumab	Zhejiang Cancer Hospital Akeso Innovent Biologics, Inc.	Phase 2	
NCT06242652	A Study to Evaluate 608 in Patients With Ankylosing Spondylitis (AS)	Drug: 608 Dose A Drug: 608 Dose B Drug: 608 Dose C Drug: Adalimumab Drug: Placebo	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Phase 2	
NCT06321289	Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL	Biological: Allogeneic CD19-STAR T cell Drug: Fludarabine Drug: Cyclophosphamide	Chinese PLA General Hospital	Phase 1 Phase 2	
NCT06323174	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	

○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06326047	A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes	Drug: NNC0519-0130 Drug: Placebo Drug: Tirzepatide	Novo Nordisk A/S	Phase 2	
NCT06326060	A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight	Drug: NNC0519-0130 Drug: Placebo Drug: Tirzepatide	Novo Nordisk A/S	Phase 2	